Literature DB >> 18064573

Recent advances on pathogenesis and therapies in systemic sclerosis.

Norihito Yazawa1, Manabu Fujimoto, Kunihiko Tamaki.   

Abstract

Systemic sclerosis (SSc) is a systemic autoimmune disease characterized by extensive fibrotic changes in various organs, including skin and lung. Although the etiology of SSc remains unknown, three major abnormalities, abnormal humoral immunity, microvasculature, and fibroblast dysfunctions are considered to play important roles. Significant progress has been made in understanding the pathogenesis on SSc, and has been also providing clues to the treatment for this disease. This review summarizes recent advances on the pathogenesis and new therapeutic strategy for SSc.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 18064573     DOI: 10.1007/s12016-007-8009-2

Source DB:  PubMed          Journal:  Clin Rev Allergy Immunol        ISSN: 1080-0549            Impact factor:   8.667


  61 in total

1.  Defective vasculogenesis in systemic sclerosis.

Authors:  Masataka Kuwana; Yuka Okazaki; Hidekata Yasuoka; Yutaka Kawakami; Yasuo Ikeda
Journal:  Lancet       Date:  2004 Aug 14-20       Impact factor: 79.321

2.  Bosentan in pulmonary arterial hypertension secondary to scleroderma.

Authors:  Amit Joglekar; Fausan S Tsai; Deborah A McCloskey; Julianne E Wilson; James R Seibold; David J Riley
Journal:  J Rheumatol       Date:  2006-01       Impact factor: 4.666

3.  Early detection of pulmonary arterial hypertension in systemic sclerosis: a French nationwide prospective multicenter study.

Authors:  Eric Hachulla; Virginie Gressin; Loïc Guillevin; Patrick Carpentier; Elisabeth Diot; Jean Sibilia; André Kahan; Jean Cabane; Camille Francès; David Launay; Luc Mouthon; Yannick Allanore; Kiet Phong Tiev; Pierre Clerson; Pascal de Groote; Marc Humbert
Journal:  Arthritis Rheum       Date:  2005-12

4.  Distinct recognition of antibodies to centromere proteins in primary Sjogren's syndrome compared with limited scleroderma.

Authors:  A C Gelber; S R Pillemer; B J Baum; F M Wigley; L K Hummers; S Morris; A Rosen; L Casciola-Rosen
Journal:  Ann Rheum Dis       Date:  2006-01-13       Impact factor: 19.103

5.  Skin score decrease in systemic sclerosis patients treated with intravenous immunoglobulin--a preliminary report.

Authors:  Y Levy; Y Sherer; P Langevitz; M Lorber; P Rotman; F Fabrizzi; Y Shoenfeld
Journal:  Clin Rheumatol       Date:  2000       Impact factor: 2.980

6.  Clinical significance of surfactant protein D as a serum marker for evaluating pulmonary fibrosis in patients with systemic sclerosis.

Authors:  Y Asano; H Ihn; K Yamane; N Yazawa; M Kubo; M Fujimoto; K Tamaki
Journal:  Arthritis Rheum       Date:  2001-06

7.  Variations of neuronal nitric oxide synthase in systemic sclerosis skin.

Authors:  Lidia Ibba-Manneschi; Sirkku Niissalo; Anna Franca Milia; Yannick Allanore; Angela Del Rosso; Alessandra Pacini; Mirko Manetti; Annarita Toscano; Paola Cipriani; Vasiliki Liakouli; Roberto Giacomelli; André Kahan; Yrjö T Konttinen; Marco Matucci-Cerinic
Journal:  Arthritis Rheum       Date:  2006-01

8.  [Bosentan for treatment of active digital ulcers in patients with systemic sclerosis].

Authors:  David Launay; Elisabeth Diot; Elisabeth Pasquier; Luc Mouthon; Nadine Boullanger; Olivier Fain; Patrick Jego; Patrick Carpentier; Pierre-Yves Hatron; Eric Hachulla
Journal:  Presse Med       Date:  2006-04       Impact factor: 1.228

9.  Clinical and serological heterogeneity in patients with anticentromere antibodies.

Authors:  Shoji Miyawaki; Hiroko Asanuma; Susumu Nishiyama; Yasuhiko Yoshinaga
Journal:  J Rheumatol       Date:  2005-08       Impact factor: 4.666

10.  Longitudinal analysis of serum cytokine concentrations in systemic sclerosis: association of interleukin 12 elevation with spontaneous regression of skin sclerosis.

Authors:  Takashi Matsushita; Minoru Hasegawa; Yasuhito Hamaguchi; Kazuhiko Takehara; Shinichi Sato
Journal:  J Rheumatol       Date:  2006-02       Impact factor: 4.666

View more
  4 in total

1.  Transcriptional regulation of Bim by FOXO3a and Akt mediates scleroderma serum-induced apoptosis in endothelial progenitor cells.

Authors:  Shoukang Zhu; Sarah Evans; Bin Yan; Thomas J Povsic; Victor Tapson; Pascal J Goldschmidt-Clermont; Chunming Dong
Journal:  Circulation       Date:  2008-11-03       Impact factor: 29.690

2.  Autoantibody-mediated regulation of B cell responses by functional anti-CD22 autoantibodies in patients with systemic sclerosis.

Authors:  M Odaka; M Hasegawa; Y Hamaguchi; N Ishiura; S Kumada; T Matsushita; K Komura; S Sato; K Takehara; M Fujimoto
Journal:  Clin Exp Immunol       Date:  2009-11-16       Impact factor: 4.330

Review 3.  T and NK Cell Phenotypic Abnormalities in Systemic Sclerosis: a Cohort Study and a Comprehensive Literature Review.

Authors:  Isabel Almeida; Sara Vieira Silva; Ana Raquel Fonseca; Ivone Silva; Carlos Vasconcelos; Margarida Lima
Journal:  Clin Rev Allergy Immunol       Date:  2015-12       Impact factor: 8.667

4.  Assessment of hospitalization and mortality of scleroderma in-patients: a thirteen-year study.

Authors:  Saeedeh Shenavandeh; Razieh Naseri
Journal:  Reumatologia       Date:  2017-08-31
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.